natgillin/translations-raw huggingface dataset:
Pipeline pressure device according to one of the preceding claims, wherein the endless conveyor members (5) are arranged symmetrically around the feed-through opening. 
Cjevovodni tlačni uređaj, prema jednom od prethodnih zahtjeva, naznačen time da su beskonačni transportni članovi (5) postavljeni simetrično oko provodnog otvora.
Pipeline pressure device according to one of the preceding claims, wherein at least one of the endless conveyor members (5) is arranged so as to be adjustable with respect to the frame in a direction transverse to the feed-through opening. 
Cjevovodni tlačni uređaj, prema jednom od prethodnih zahtjeva, naznačen time da je najmanje jedan od beskonačnih transportnih članova (5) postavljen tako da ga se može prilagođavati u odnosu na okvir u smjeru poprečnom prema provodnom otvoru.
Pipeline pressure device according to one of the preceding claims, wherein the frame has dimensions corresponding to a standard 20-foot (6.096-metre) container. 
Cjevovodni tlačni uređaj, prema jednom od prethodnih zahtjeva, naznačen time da okvir ima dimenzije koje odgovaraju standardnom 20-stopnom (6,096 m) kontejneru.
Pipeline pressure device according to one of the preceding claims, wherein the drive can be activated for adjustably varying the speed and thrust A of the endless conveyor members (5). 
Cjevovodni tlačni uređaj, prema jednom od prethodnih zahtjeva, naznačen time da se pogon može aktivirati za prilagodno mijenjanje brzine i potiska A beskonačnih transportnih članova (5).
Pipeline pressure device according to one of the preceding claims, wherein the longitudinal part (5') of the endless conveyor member (5) has a length of at least 0.6 m at the side of the feed-through opening. 
Cjevovodni tlačni uređaj, prema jednom od prethodnih zahtjeva, naznačen time da uzdužni dio (5') beskonačnog transportnog člana (5) ima dužinu od najmanje 0,6 m na strani od provodnog otvora.
Pipeline pressure device according to one of the preceding claims, wherein the endless conveyor members (5) and drive are configured for together exerting a thrust A on the conveyor pipeline (6) of at least 500 kN. 
Cjevovodni tlačni uređaj, prema jednom od prethodnih zahtjeva, naznačen time da su beskonačni transportni članovi (5) i pogon konfigurirani za zajedničko stvaranje potiska A na transportni cjevovod (6) od najmanje 500 kN.
Pipeline pressure device according to one of the preceding claims, wherein the longitudinal parts (5') of the endless conveyor members (5) extend substantially in the horizontal direction at the side of the feed-through opening. 
Cjevovodni tlačni uređaj, prema jednom od prethodnih zahtjeva, naznačen time da se uzdužni dijelovi (5') beskonačnih transportnih članova (5) protežu znatno u vodoravnom smjeru na strani od provodnog otvora.
System for the directional horizontal drilling in the ground of a shank (10) and for subsequently bringing a conveyor pipeline (6) into the shank (10), comprising: 
Sustav za usmjereno vodoravno bušenje provrta (10) u zemlji i zatim za uvođenje transportnog cjevovoda (6) u provrt (10), obuhvaća:
a drill pipeline (13) with a drill head provided thereon; 
bušaći cjevovod (13) s bušaćom glavom postavljenom na njemu;
a conveyor pipeline (6); 
transportni cjevovod (6);
at least one pipeline pressure device (1) according to one of the preceding claims for reducing, by driving the endless conveyor members (5), tensile forces on the conveyor pipeline (6) during drawing inward into the drilled-out shank (10). 
najmanje jedan cjevovodni tlačni uređaj (1), prema jednom od prethodnih zahtjeva, za smanjenje, pogonjenim beskonačnim transportnim članovima (5), vlačne sile na transportnom cjevovodu (6) za vrijeme uvlačenja u izbušeni provrt (10).
System according to claim 12, wherein at least two pipeline pressure devices connected in series are provided. 
Sustav, prema zahtjevu 12., naznačen time da su postavljena najmanje dva cjevovodna tlačna uređaja (1) povezana u seriju.
System according to claim 12 or 13, wherein the drill-pulling device (15) is arranged at a starting point of the shank (10) to be drilled out and the pipeline pressure device (1) is arranged at an end point of the shank (10) to be drilled out. 
Sustav, prema zahtjevima 12. ili 13., naznačen time da je uređaj (15) za povlačenje bušilice postavljen na početnu točku provrta (10) kojega treba izbušiti i da je cjevovodni tlačni uređaj (1) postavljen na krajnju točku provrta (10) kojega treba izbušiti.
arranging a drill-pulling device (15) at a starting point of a shank to be drilled out; 
postavljanje uređaja (15) za povlačenje bušilice na početnu točku provrta kojega treba izbušiti;
arranging at least one pipeline pressure device (1) according to one of the preceding claims at an end point of the shank (10) to be drilled out; 
postavljanje najmanje jednog cjevovodnog tlačnog uređaja (1), prema jednom od prethodnih zahtjeva, na krajnju točku provrta (10) kojega treba izbušiti;
the directional feeding, with the aid of the drill-pulling device (15) at least partially in the horizontal direction, of a drill pipeline (13) with a drill head provided thereon for drilling out the shank (10); 
usmjereno uvlačenje, pomoću uređaja (15) za povlačenje bušilice u barem djelomično vodoravnom smjeru, bušaćeg cjevovoda (13) s bušaćom glavom postavljenom na njemu radi bušenja provrta (10);
coupling a conveyor pipeline (6) to the drill pipeline (13); 
priključenje transportnog cjevovoda (6) na bušaći cjevovod (13);
The specific binding protein of Claim 5, wherein said binding fragment is selected from the group consisting of Fab, Fab' or F(ab')2 and Fv. 
Specifični vezni protein iz Zahtjeva 5, naznačen time da je navedeni vezni fragment odabran iz skupine koja se sastoji od Fab, Fab’ ili F(ab’)2 i Fv.
A nucleic acid molecule encoding the specific binding protein of any one of claims 1 to 6. 
Molekula nukleinske kiselina naznačena time da kodira specifični vezni protein iz bilo kojeg od Zahtjeva 1 do 6.
Use of the specific binding protein of any one of Claims 1 to 6 in the preparation of a medicament for the treatment of a malignant tumor. 
Korištenje specifičnog veznog proteina iz bilo kojeg od Zahtjeva 1 do 6 naznačeno time da u pripremi lijeka za liječenje zloćudnog tumora.
The use of Claim 13 or 14, wherein said medicament is for use in conjunction with or following a conventional surgery, a bone marrow stem cell transplantation or a peripheral stem cell transplantation. 
Primjena Zahtjeva 13 ili 14, naznačena time da je navedeni lijek namijenjen za primjenu tijekom ili nakon konvencionalne operacije, presađivanja matičnih stanica koštane srži ili presađivanja perifernih matičnih stanica.
A conjugate comprising the antibody of Claim 5 or a binding fragment thereof and a therapeutic agent. 
Konjugat naznačen time da se sastoji od antitijela iz Zahtjeva 5 ili veznog fragmenta istog i terapijskog agensa.
The refrigerant composition according to claim 1 comprising 36 to 42 mass% of 1,1,1,2-tetrafluoroethane (HFC134a) and 58 to 64 mass% of 2,3,3,3-tetrafluoropropene (HFO1234yf). 
Rashladni sastav prema zahtjevu 1, naznačen time, da sadrži 36 do 42 masenih postotaka 1,1,1,2-tetrafluoroetana (HFC134a) i 58 do 64 masenih postotaka 2,3,3,3-tetrafluoropropana (HFO1234yf).
The refrigerant composition according to claim 1, which further comprises a polymerization inhibitor. 
Rashladni sastav prema zahtjevu 1, naznačen time, da nadalje sadrži inhibitor polimerizacije.
The refrigerant composition according to claim 1, which further comprises a drying agent. 
Rashladni sastav prema zahtjevu 1, naznačen time, da nadalje sadrži sredstvo za sušenje.
The composition of claim 3, wherein said PEG-IFN-β is present at a concentration of 0.044 mg/ml, 0.055 mg/ml or 0.110 mg/ml. 
Pripravak prema zahtjevu 3, naznačen time da navedeni PEG-I FN- β je prisutan u koncentraciji od 0.044 mg/ml, 0.055 mg/ml ili 0.110 mg/ml.
The composition of claim 5, wherein the PEG has a molecular weight of at least 20 kDa, preferably at least 40 kDa, more preferably 40 kDa. 
Pripravak prema zahtjevu 5, naznačen time da PEG ima molekularnu težinu od najmanje 20 kDa, poželjno barem 40 kDa, još poželjnije 40 kDa.
The composition of claim 1 or 2, wherein said poloxamer 188 is present at a concentration of 0.4 mg/ml to 0.7 mg/ml. 
Pripravak prema zahtjevu 1 ili 2, naznačen time da navedeni poloksamer 188 je prisutan u koncentraciji od 0.4 mg/ml do 0.7 mg/ml.
The composition of claim 1 or 2, wherein said poloxamer 188 is present at a concentration of 0.5 mg/ml. 
Pripravak prema zahtjevu 1 ili 2, naznačen time da navedeni poloksamer 188 je prisutan u koncentraciji od 0.5 mg/ml.
A method for preparing a liquid pharmaceutical composition according to any of claims 1-17, wherein said method comprises adding a calculated amount of a polyol excipient and poloxamer 188 to the sodium acetate buffered solution and then adding the PEG-IFN-beta. 
Postupak za dobivanje tekućeg farmaceutskog pripravka prema bilo kojem od zahtjeva 1-17, naznačen time da navedeni postupak sadrži dodavanje proračunate količine pomoćne tvari poliola i poloksamera 188 u pufersku otopinu natrijevog acetata i zatim se dodaje PEG-IFN-beta.
The container of claim 19, wherein said container is a pre-filled syringe, or a vial for an auto-injector. 
Spremnik prema zahtjevu 19, naznačen time navedeni spremnik je prethodno napunjena štrcaljka ili bočica za auto-injektorski uređaj.
A fan assembly as claimed in claim 1, wherein the flexible sealing member is connected to the impeller housing (64). 
Ventilatorski sustav prema zahtjevu 1, gdje je fleksibilni zatvarač spojen na kućište propelera (64).
A fan assembly as claimed in claim 1 or claim 2, wherein the flexible sealing member is biased against the outer casing (16). 
Ventilatorski sustav prema zahtjevu 1 ili zahtjevu 2, gdje je fleksibilni zatvarač u odnosu na vanjsko kućište (16) odmaknut.
A fan assembly as claimed in claim 8, wherein said means comprises at least one curved vane (65a, 65b). 
Ventilatorski sustav prema zahtjevu 8, gdje navedena sredstva obuhvaćaju barem jednu zakrivljenu lopaticu (65a, 65b).
A fan assembly as claimed in claim 9, wherein the or each vane (65a, 65b) is shaped to change the direction of the air flow by around 90°. 
Ventilatorski sustav prema zahtjevu 9, gdje je svaka lopatica (65a, 65b) oblikovana tako da mijenja smjer struje zraka za oko 90°.
R7, R8, R9, R10 and R11 independently represent hydrogen, halogen, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or phenyl, and any of said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or phenyl is optionally substituted with 1, 2 or 3 halogen atoms; or R10 and R11 together with the carbon atoms to which they are attached form a benzene ring which is optionally substituted with 1, 2 or 3 halogen atoms; 
, R8, R9, R10 i R11 neovisno predstavljaju vodik, halogen, cijano, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C3-6 cikloalkil ili fenil, gdje je bilo koji od navedenih C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C3-6 cikloalkila ili fenila izborno supstituiran s 1, 2 ili 3 atoma halogena; ili R10 i R11, zajedno s atomima ugljika na koje su vezani, tvore benzenski prsten, izborno supstituiran s 1, 2 ili 3 atoma halogena;
R4, R5 and R6 independently represent hydrogen or fluorine; and 
, R5 i R6 neovisno predstavljaju vodik ili fluor; i
R7, R8, R9, R10 and R11 independently represent hydrogen, halogen, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, or phenyl; and any of said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or phenyl may be optionally substituted with 1, 2 or 3 halogen atoms; with the proviso that when R7 and R11 independently represent hydrogen or fluorine, at least one of R8, R9 and R10 is a halogen atom. 
, R8, R9, R10 i R11 neovisno predstavljaju vodik, halogen, cijano, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C3-6 cikloalkil, ili fenil; gdje bilo koji od navedenih C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C3-6 cikloalkila ili fenila može biti izborno supstituiran s 1, 2 ili 3 atoma halogena; uz uvjet da kada R7 i R11 neovisno predstavljaju vodik ili fluor, najmanje jedan od R8, R9 i R10 je atom halogena.
R4, R5 and R6 independently represent hydrogen or methyl; and 
, R5 i R6 neovisno predstavljaju vodik ili metil; i
R7, R8, R9, R10 and R11 independently represent hydrogen, chlorine, fluorine, bromine, methyl or trifluoromethyl. 
, R8, R9, R10 i R11 neovisno predstavljaju vodik, klor, fluor, brom, metil ili trifluormetil.
A compound of formula (I) or a salt thereof, as defined in claim 1, which is N- {[2-chloro-3-(trifluoromethyl)phenyl]methyl}-1-methyl-5-oxoprolinamide or a pharmaceutically acceptable salt thereof. 
Spoj formule (I), ili njegova sol, u skladu s patentnim zahtjevom 1, naznačen time što je N-{[2-klor-3-(trifluormetil)fenil]metil}-1-metil-5-oksoprolinamid, ili njegova farmaceutski prihvatljiva sol.
A compound of formula (I) or a salt thereof, as defined in claim 1, which is N- {[2-chloro-3-(trifluoromethyl)phenyl]methyl}-1-methyl-5-oxo-L-prolinamide or a pharmaceutically acceptable salt thereof. 
Spoj formule (I), ili njegova sol, u skladu s patentnim zahtjevom 1, naznačen time što je N-{[2-klor-3-(trifluormetil)fenil]metil}-1-metil-5-okso-1-prolinamid, ili njegova farmaceutski prihvatljiva sol.
R4, R5 and R6 independently represent hydrogen, fluorine or methyl; and 
, R5 i R6 neovisno predstavljaju vodik, fluor ili metil; i
R7, R8, R9, R10 and R11 independently represent hydrogen, halogen, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or phenyl, and any of said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or phenyl is optionally substituted with 1, 2 or 3 halogen atoms; or R10 and R11 together with the carbon atoms to which they are attached form a benzene ring which is optionally substituted with 1, 2 or 3 halogen atoms; 
, R8, R9, R10 i R11 neovisno predstavljaju vodik, halogen, cijano, C1-6 alkil, C2-6 alkinil, C2-6 alkenil, C3-6 cikloalkil ili fenil, gdje je bilo koji od navedenih C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C3-6 cikloalkila ili fenila izborno supstituiran s 1, 2 ili 3 atoma halogena; ili R10 i R11, zajedno s atomima ugljika na koje su vezani, tvore benzenski prsten, izborno supstituiran s 1, 2 ili 3 atoma halogena;
A compound of formula (I), or a salt thereof, for use in the treatment or prevention of pain, inflammation or a neurodegenerative disease as defined in any one of claims 11 to 13, wherein the use is for the treatment or prevention of inflammatory pain, neuropathic pain or visceral pain, or for the treatment or prevention of Alzheimer's disease. 
Spoj formule (I), ili njegova sol, namijenjen upotrebi u liječenju ili sprječavanju boli, upale ili neurodegenerativne bolesti u skladu s bilo kojim od patentnih zahtjeva 11 do 13, naznačen time što je upotreba namijenjena liječenju ili sprječavanju upalne boli, neuropatske boli ili visceralna boli, ili liječenju ili sprječavanju Alzheimerove bolesti.
A compound as claimed in any of claims 1 to 9, for use in the treatment of asthma, chronic obstructive pulmonary disease, rhinitis, allergic airway syndrome, or allergic rhinobronchitis. 
Spoj prema bilo kojem od zahtjeva 1 do 9, za uporabu u liječenju astme, kronične opstruktivne plućne bolesti, rinitisa, sindroma alergije dišnih putova ili alergijskog rinobronhitisa.
each R4 independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group; or two R4 on the same nitrogen atom, taken together with the nitrogen atom form an optionally substituted 5- to 6-membered heteroaryl or 4- to 8-membered heterocyclyl ring having, in addition to the nitrogen atom, 0-2 ring heteroatoms selected from N, O, and S; 
svako R4 nezavisno je vodik ili alifatična, aril, heteroaril ili heterociklil grupa; ili dva R4 na istom atomu dušika, zajedno sa atomom dušika formiraju 5- do 6-člani heteroaril ili 4- do 8-člani heterociklil prsten koji ima, pored atoma dušika, 0-2 heteroatoma u prstenu izabrana od N, O i S;
A compound according to claim 17, wherein R9 is selected from a substituted C2-C12 alkenyl and a substituted C4-C12 alkenynyl that are substituted in one or more positions with halogen, OR', =O, OCOR', OCONHR', OCONR'R', CONHR', CONR'R' and protected OH, wherein each of the R' groups is independently selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl and substituted or unsusbtituted aryl. 
Spoj prema patentnom zahtjevu 16, naznačen time što je R9 supstituirani C2-C12 alkenil koji je supstituiran na jednom ili više položaja sa halogenom, OR', =O, OCOR', OCONHR', OCONR'R', CONHR', CONR'R' i zaštićenim OH, pri čemu je svaka od R' grupa nezavisno izabrana od vodika, supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila, supstituiranog ili nesupstituiranog C2-C12 alkinila i supstituiranog ili nesupstituiranog arila.
each R4 independently is hydrogen or an aliphatic, aryl, heteroaryl, or heterocyclyl group; or two R4 on the same nitrogen atom, taken together with the nitrogen atom form a 5- to 6-membered heteroaryl or 4- to 8-membered heterocyclyl ring having, in addition to the nitrogen atom, 0-2 ring heteroatoms selected from N, O, and S; 
svako R4 nezavisno je vodik ili alifatična, aril, heteroaril ili heterociklil grupa; ili dva R4 na istom atomu dušika, zajedno sa atomom dušika formiraju 5- do 6-člani heteroaril ili 4- do 8-člani heterociklil prsten koji ima, pored atoma dušika, 0-2 heteroatoma u prstenu izabrana od N, O i S;
An information storage means that can be read by a computer or a microprocessor storing instructions of a computer program, that permits the implementation of a method according to any one of claims 1 to 7 or 9. 
Sredstva za pohranu informacija koja mogu biti pročitana putem pohranjenih instrukcija u računalu ili mikroprocesoru u vidu računalnog programa, naznačena time da omogućavaju primjenu postupka prema bilo kojem od zahtjeva 1 do 5.
A computer program loadable into a computer system, said program containing instructions enabling the implementation of the method according to any one of claims 1 to 7 or 9, when that program is loaded and executed by a computer system. 
Računalni program koji se može učitati u računalni sustav, naznačen time da navedeni program sadrži instrukcije koje omogućavaju primjenu postupka prema bilo kojem od zahtjeva 1 do 5, kada je navedeni program učitan i izvršava se na računalnom sustavu.
A propulsion apparatus according to claim 3 or 4, characterized in that said fin pitching axle (20) and the fin axle (6) are the same. 
Pogonski uređaj prema zahtjevu 3 ili 4, naznačen time da su navedene osovine za zakretanje peraje oko poprečne linije (20) i osovina sa perajom (6) iste.
A propulsion apparatus according to claim 6, characterized in that said fin axle (6) is parallel to said fin pitching axle (20). 
Pogonski uređaj prema zahtjevu 6, naznačen time da je navedena osovina sa perajama (6) paralelna sa navedenom osovinom za zakretanje peraje oko poprečne linije (20).
A propulsion apparatus according to claim 6, characterized in that said apparatus comprises two or more fins (6) connected to said same fin pitching axle (20) via one or more synchronizing links (22). 
Pogonski uređaj prema zahtjevu 6, naznačen time da navedeni uređaj sadrži dvije ili više peraja (6) spojenih na istu navedenu osovinom za zakretanje peraje oko poprečne linije (20) pomoću jedne ili više sinkronizacijskih veza (22).
A method of propelling a ship by means of a propulsion apparatus according to any of the preceding claims wherein said heave and said pitch mechanism are connected to a single crank (10) on said crankshaft (9), or two separate cranks having substantially the same radius and angular position with respect to the axis of rotation (13) of said crankshaft (9). 
Postupak za pogon broda pomoću pogonskog uređaja prema bilo kojem od prethodnih zahtjeva naznačen time da su navedeni mehanizma za poniranje i navedeni mehanizam za zakretanje oko poprečne linije spojeni na jedno vratilo (10) na navedenoj radilici (9), ili dva odvojena vratila koja imaju u osnovi isti radijus i kutni položaj u odnosu na os rotacije (13) navedene radilice (9).
The FGF-21 polypeptide of claim 1, wherein the non-naturally encoded amino acid comprises a carbonyl group, an aminooxy group, a hydrazine group, a hydrazide group, a semicarbazide group, an azide group, or an alkyne group. 
FGF-21 polipeptid prema zahtjevu 1, gdje aminokiselina koja nije prirodno kodirana obuhvaća karbonilnu skupinu, aminooksi skupinu, hidrazinsku skupinu, hidrazidnu skupinu, semikarbazidnu skupinu, azidnu skupinu ili alkinsku skupinu.
The FGF-21 polypeptide of claim 7, wherein the non-naturally encoded amino acid comprises a carbonyl group. 
FGF-21 polipeptid prema zahtjevu 7, gdje aminokiselina koja nije prirodno kodirana obuhvaća karbonilnu skupinu.
The FGF-21 polypeptide of claim 1, which is made by reacting a FGF-21 polypeptide comprising a carbonyl-containing amino acid with a water soluble polymer comprising an aminooxy, hydrazine, hydrazide or semicarbazide group. 
FGF-21 polipeptid prema zahtjevu 1, koji nastaje reakcijom FGF-21 polipeptida koji obuhvaća aminokiselinu koja sadrži karbonil s u vodi topljivim polimerom koji obuhvaća aminooksi, hidrazin, hidrazid ili semikarbazid skupinu.
The FGF-21 polypeptide of claim 1, which is made by reacting a water soluble polymer comprising a carbonyl group with a polypeptide comprising a non-naturally encoded amino acid that comprises an aminooxy, a hydrazine, a hydrazide or a semicarbazide group. 
FGF-21 polipeptid prema zahtjevu 1, koji nastaje reakcijom u vodi topljivog polimera koji obuhvaća karbonilnu skupinu s polipeptidom koji obuhvaća aminokiselinu koja nije prirodno kodirana i sadrži aminooksi, hidrazin, hidrazid ili semikarbazid skupinu.
The FGF-21 polypeptide of claim 1, wherein the non-naturally encoded amino acid comprises a saccharide moiety. 
FGF-21 polipeptid prema zahtjevu 1, gdje aminokiselina koja nije prirodno kodirana sadrži saharidni dio.
A composition comprising the FGF-21 polypeptide of claim 19 and a pharmaceutically acceptable carrier. 
Smjesa koja sadrži FGF-21 polipeptid prema zahtjevu 19 i farmaceutski prihvatljivi nosač.
A FGF-21 polypeptide according to claim 1, comprising a water soluble polymer linked by a covalent bond to the FGF-21 polypeptide at the non-naturally occurring amino acid. 
FGF-21 polipeptid prema zahtjevu 1, sadrži u vodi topljivi polimer povezan kovalentnom vezom za FGF-21 polipeptid na aminokiselini koja nije prirodno kodirana.
The FGF-21 polypeptide of claim 7 wherein said non-naturally encoded amino acid is linked to a poly(ethylene glycol) molecule. 
FGF-21 polipeptid prema zahtjevu 7 gdje je aminokiselina koja nije prirodno kodirana povezana za poli(etilen glikol) molekulu.
A FGF-21 polypeptide according to claim 1, comprising at least one linker, polymer, or biologically active molecule, wherein said linker, polymer, or biologically active molecule is attached to the polypeptide through a functional group of the non-naturally encoded amino acid, which is ribosomally incorporated into the polypeptide. 
FGF-21 polipeptid prema zahtjevu 1, sadrži barem jedan linker, polimer, ili biološki aktivnu molekulu, gdje je taj linker, polimer, ili biološki aktivna molekula spojen za polipeptid preko funkcionalne skupine aminokiseline koja nije prirodno kodirana, a koja je ribosomalno ugrađena u polipeptid.
A FGF-21 polypeptide according to claim 1, comprising a linker, polymer or biologically active molecule that is attached to the non-naturally encoded amino acid, wherein said non-naturally encoded amino acid is ribosomally incorporated into the polypeptide. 
FGF-21 polipeptid prema zahtjevu 1, sadrži linker, polimer, ili biološki aktivnu molekulu spojen za aminokiselinu koja nije prirodno kodirana, gdje ta aminokiselina koja nije prirodno kodirana je ribosomalno ugrađena u polipeptid.
The FGF-21 polypeptide of claim 1, wherein the non-naturally encoded amino acid comprises a ketone group. 
FGF-21 polipeptid prema zahtjevu 1, gdje aminokiselina koja nije prirodno kodirana sadrži ketonsku skupinu.